甲泼尼松龙联合施普善治疗急性视神经炎疗效观察

目的:甲泼尼松龙大剂量冲击疗法和施普善辅助治疗对严重急性视神经炎的疗效观察。方法:28例(42眼)失明的急性视神经炎,采用静脉滴入大剂量甲泼尼松龙1.0g冲击疗法,配合施普善20mL,ATP40mg静脉滴注。结果:28例(42眼)视力均有不同程度的提高,总有效率为93%。部分患者追踪随访0.5a视力能有提高和巩固。结论:甲泼尼松龙冲击疗法治疗时间短,疗效高,作用迅速,副作用少,无复发。配合施普善治疗疗效更显著。     

天然脑活素促细胞增殖和抗细胞衰老作用的研究

目的:探讨天然脑活素对人胚肺二倍体成纤维细胞(MRC-5)增殖能力和复制性衰老的影响及其机理。方法:光镜下观察MRC-5细胞衰老表型,常规计数细胞代龄、传代速度,MTT法检测细胞增殖活度,X-Gal染色法观察细胞衰老情况,计数衰老细胞百分率。结果:天然脑活素可维持细胞的非衰老表型,增加MRC-5细胞代龄,天然脑活素孵育MRC-5细胞的细胞增殖能力较空白老龄对照组明显升高(P<0.05),细胞的增殖速度显著加快。另外,天然脑活素连续培养的细胞在老龄阶段衰老细胞数显著低于老龄对照细胞(P<0.01)。结论:天然脑活素可升高MRC-5细胞增殖能力,有效延缓细胞的复制性衰老。     

新生大鼠缺氧缺血性脑病模型脑组织钙调蛋白测定及脑活素治疗作用

目的：研究脑组织中钙调蛋白(CaM)含量与新生大鼠缺氧缺血性脑病(HIE)发病机制的关系及脑活素的治疗作用。方法：在建立新生大鼠HIE模型的基础上,采用依赖环核苷酸的磷酸二酯酶(PDE)法检测103只大鼠(其中对照组15只,实验组88只分3组)脑组织CaM含量,结合病理切片和透射电镜观察脑组织病理改变,同时通过侧脑室及肌内两种途径给予脑活素治疗。结果：HIE组脑组织CaM含量均明显增高,24 h(521.27±46.04) μg/g脑组织;48 h(509.52±35.98) μg/g脑组织;72 h(421.05±31.81) μg/g脑组织,与正常组(187.63±54.22)比较差异有显著性(P<0.01);治疗组CaM含量均明显降低,侧脑室注射组：24 h(435.21±56.17) μg/g脑组织;48 h(260.38±32.43) μg/g脑组织;72 h(197.64±19.21) μg/g脑组织;肌内注射组：24 h(441.04±30.66) μg/g脑组织;48 h(305.39±32.99) μg/g脑组织;72 h(217.71±52.89) μg/g脑组织;与HIE组比较差异有显著性(P<0.01),接近正常组水平。在神经元变性、坏死和间质水肿等方面,治疗组明显轻于HIE组。结论：CaM含量异常升高在HIE的发病环节中起一定作用。脑活素治疗HIE的机制可能与其显著降低脑组织中CaM含量有关。     

Peptide profiling of Internet‐obtained Cerebrolysin using high performance liquid chromatography – electrospray ionization ion trap and ultra high performance liquid chromatography – ion mobility – quadrupole time of flight mass spectrometry

Cerebrolysin, a parenteral peptide preparation produced by controlled digestion of porcine brain proteins, is an approved nootropic medicine in some countries. However, it is also easily and globally available on the Internet. Nevertheless, until now, its exact chemical composition was unknown. Using high performance liquid chromatography (HPLC) coupled to ion trap and ultra high performance liquid chromatography (UHPLC) coupled to quadrupole‐ion mobility‐time‐of‐flight mass spectrometry (Q‐IM‐TOF MS), combined with UniProt pig protein database search and PEAKS de novo sequencing, we identified 638 unique peptides in an Internet‐obtained Cerebrolysin sample. The main components in this sample originate from tubulin alpha‐ and beta‐chain, actin, and myelin basic protein. No fragments of known neurotrophic factors like glial cell‐derived neurotrophic factor (GDNF), neurotrophin nerve growth factor (NGF), brain‐derived neurotrophic factor (BDNF), and ciliary neurotrophic factor (CNTF) were found, suggesting that the activities reported in the literature are likely the result of new, hitherto unknown cryptic peptides with nootropic properties. Copyright © 2015 John Wiley & Sons, Ltd.     

Protective effects of cerebrolysin in a rat model of optic nerve crush

To investigate the effects of cerebrolysin (Cbl) on optic nerves (ON) and retinal ganglion cells (RGC) in a rat model of ON crush. Rats received intravitreal injection of Cbl (n = 20), intra-ON injection of Cbl (n = 20), intraperitoneal injection (IPI) of Cbl (n = 20), or phosphate buffered saline (PBS; n = 20) every day for 2 weeks after ON crush injury. At 3 weeks post-trauma, RGC density was counted by retrograde labeling with FluoroGold and visual function was assessed by flash visual-evoked potentials. Activities of microglia after insults were quantified by immunohistochemical analysis of the presence of ED1 in the optic nerve. At 3 weeks postcrush, the densities of RGCs in the Cbl-IVI group (1125 ± 166/mm²) and in the Cbl-IPI treatment group (1328 ± 119/mm²) were significantly higher than those in the PBS group (641 ± 214/mm²). The flash visual-evoked potential measurements showed that latency of the P1 wave was significantly shorter in the Cbl-IVI- and Cbl-IPI-treated groups (105 ± 4 ms and 118 ± 26 ms, respectively) than in the PBS-treated group (170 ± 20 ms). However, only Cbl IPI treatment resulted in a significant decrease in the number of ED1-positive cells at the lesion sites of the ON (5 ± 2 cells/vs. 30 ± 4 cells/high-power field in control eyes). Treatment with intra-ON injection of Cbl was harmful to the optic nerve in the crush model. Systemic administration of Cbl had neuroprotective effects on RGC survival and visual function in the optic nerve crush model.     

Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer’s Disease

Serum vascular endothelial growth factor (VEGF) increases with Alzheimer’s disease (AD) severity and may prevent cognitive decline. However, information on the influence of AD drug therapy on circulating VEGF is limited. This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial. Treatment with Cerebrolysin plus donepezil reduced elevated serum VEGF levels and improved functioning and cognition significantly compared with donepezil alone in patients with advanced AD, and treatment differences were more pronounced in patients with higher VEGF levels. Our results indicate that the combined therapy reversed the increase of serum VEGF in advanced AD, which was associated with cognitive and functional responses, particularly in patients with high baseline VEGF.     

鲎试剂法用于脑活素针剂细菌内毒素的检测

本文采用增强或抑制试验,对进口的脑活素针剂进行了细菌内毒素检测考察。据三批实验结果表明,脑活素针剂80倍稀释液对灵敏度为0.125Eu/ml的鲎试剂无增强或抑制作用,故本品适用于鲎试剂作内毒素检查。     

葛根素辅助脑活素治疗缺血性脑血管疾病

目的:观察葛根素注射液辅助脑活素注射液治疗缺血性脑血管疾病的效果.方法:治疗组42例,用20 ml脑活素加入 0.9%氯化钠注射液250 ml,静脉滴注,qd,再用400 mg葛根素加入5%葡萄糖注射液或0.9%氯化钠注射液500 ml,静脉滴注 ,qd.对照组42例,单用400 mg葛根素加入10%葡萄糖或0.9%氯化钠注射液500 ml静脉滴注,qd,两组均20 d为1疗程.结果:治疗组有效率97.61%,对照组有效率88.10%.结论:葛根素注射液与脑活素注射液联用治疗缺血性脑血管疾病效果优于单用葛根素注射液.     

激光辐射充氧液、胞二磷胆碱、脑活素治疗新生儿缺氧缺血性脑病56例临床观察

目的 :观察激光辐射充氧液、胞二磷胆碱、脑活素对新生儿缺氧缺血性脑病 (HIE)的治疗效果。方法 :10 8例随机分为对照组和治疗组 ,前者的治疗包括给氧、抗菌、纠酸、降颅压、静脉给予能量合剂和对症治疗 ,后者除这些常规治疗外 ,另给激光辐射充氧液、胞二磷胆碱、脑活素治疗 ;观察临床症状消失时间 ,并随访观察HIE患儿神经系统后遗症情况。结果 :近期疗效观察 ,治疗组临床症状消失时间较对照组明显提前 ,治疗组总有效率 (94 6 % ) ,明显优于对照组 (73 1% ) (P <0 0 1) ;远期疗效观察 ,治疗组后遗症较对照组明显减少 (11 5 %vs 34 0 % ) ,差异具有显著性 (P <0 0 5 )。结论 :早期应用激光辐射充氧液、胞二磷胆碱、脑活素联合治疗新生儿HIE疗效确切 ,能改善预后。     

新生儿缺氧缺血性脑病早期治疗及预后分析

目的:探讨新生儿缺氧缺血性脑病早期治疗的临床效果。方法:收集近期北京市房山区妇幼保健院儿科收治的50例新生儿缺氧缺血性脑病患儿作为观察组,并将之前采用常规治疗的20例患儿作为对照组,观察组在对照组的基础上联合脑活素及复方丹参注射液,分析比较两组临床疗效。结果:观察组显效率、总有效率分别为56.0%、98.0%,均显著优于常规治疗的对照组(P<0.05),观察组治疗1个疗程后与出生后4周NBNA评分均明显优于对照组(P<0.05),两组不良反应率均较低。结论:脑活素及复方丹参注射液联合治疗新生儿缺氧缺血性脑病的临床疗效确切,且安全性良好。